Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Non-Current Deffered Revenue (2016 - 2018)

Moleculin Biotech (MBRX) has 3 years of Non-Current Deffered Revenue data on record, last reported at $107000.0 in Q4 2018.

  • For Q4 2018, Non-Current Deffered Revenue fell 28.67% year-over-year to $107000.0; the TTM value through Dec 2018 reached $107000.0, down 28.67%, while the annual FY2018 figure was $107000.0, 28.67% down from the prior year.
  • Non-Current Deffered Revenue reached $107000.0 in Q4 2018 per MBRX's latest filing, up from $92000.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $150000.0 in Q2 2017 and bottomed at $12500.0 in Q2 2016.
  • Average Non-Current Deffered Revenue over 3 years is $113833.3, with a median of $125000.0 recorded in 2017.
  • Peak YoY movement for Non-Current Deffered Revenue: soared 1100.0% in 2017, then tumbled 38.67% in 2018.
  • A 3-year view of Non-Current Deffered Revenue shows it stood at $88000.0 in 2016, then soared by 70.45% to $150000.0 in 2017, then decreased by 28.67% to $107000.0 in 2018.
  • Per Business Quant database, its latest 3 readings for Non-Current Deffered Revenue were $107000.0 in Q4 2018, $92000.0 in Q3 2018, and $150000.0 in Q1 2018.